Latest 8-K filings

Blackstone Secured Lending Fund announced a material amendment to its senior secured credit agreement, extending maturity dates and adjusting commitment amounts.

Energous Corporation announced robust second quarter 2026 financial results, showcasing a 217% year-over-year revenue increase and achieving its sixth consecutive quarter of revenue growth.

Toppoint Holdings Inc. announced its second quarter 2026 financial results, showcasing a 17% year-over-year revenue increase to $4.6 million and an 80% reduction in net loss, driven by a strategic shift towards higher-value import and metal loads.

Atea Pharmaceuticals announced positive Phase 3 results for its BEM/RZR regimen in treating Hepatitis C, alongside progress in its Hepatitis E drug development.

Norwegian Cruise Line Holdings Ltd. has officially confirmed that advisory votes on executive compensation will be held annually, aligning with shareholder preference expressed at the 2026 Annual General Meeting.

AEON Biopharma reported Q2 2026 results, highlighting a $15.3 million financing with milestone warrants and continued progress in developing its ABP-450 biosimilar to BOTOX.

AEVEX Corp. reported a near doubling of Q2 revenue to $201.8 million and swung to a net income of $6.7 million, while also announcing a strategic acquisition of BlackSea Technologies.

ECA Marcellus Trust I declared a quarterly distribution of $0.001 per unit, continuing its strategy of building cash reserves for future expenses.

Interpace Biosciences announced Q2 2026 results, with thyroid revenue up 9% year-over-year to $9.1 million, alongside improved income from continuing operations and Adjusted EBITDA.

Forward Industries reported a substantial increase in SOL holdings and SOL per share for fiscal Q3 2026, alongside strategic investments and share repurchases, while also disclosing significant non-cash impairments on digital assets.

Generation Income Properties received a notice from Nasdaq indicating continued non-compliance with the minimum bid price rule and an additional deficiency in market value of publicly held shares, jeopardizing its listing.

Connect Biopharma announced second quarter 2026 financial results, highlighting the completion of enrollment in Phase 2 Seabreeze STAT studies for asthma and COPD exacerbations, with topline results expected in September 2026.

Allogene Therapeutics reported second quarter 2026 financial results and provided a corporate update, highlighting progress in its pivotal ALPHA3 trial for cema-cel and its RESOLUTION trial for ALLO-329.

Lucid Group announced the filing of a prospectus supplement to register for resale specific shares of Series C Convertible Preferred Stock and Class A Common Stock previously issued in private placements.

Enovix Corporation announced second quarter 2026 results, showcasing a 21% year-over-year revenue increase to $9.0 million and significant progress in smartphone and smart eyewear battery development.

Alpha and Omega Semiconductor reported fiscal year 2026 results with a net loss and declining revenue, but provided guidance for Q1 FY27 with expected revenue growth and improved gross margins.

SeaStar Medical announced Q2 2026 financial results, showcasing an 82% increase in QUELIMMUNE net revenue and advancements in its NEUTRALIZE-AKI trial, alongside obtaining crucial billing codes.

Ascend Wellness Holdings announced Q2 2026 results, showing a 7.9% sequential increase in net revenue to $126.1 million and a rise in Adjusted EBITDA to $29.1 million, alongside retail footprint expansion.

Atara Biotherapeutics announced second quarter 2026 financial results and operational progress, including a productive FDA meeting for tabelecleucel and significant cost reductions.

Acrivon Therapeutics announced its second quarter 2026 financial results, highlighting progress in its ACR-368 and ACR-2316 clinical programs and providing an updated cash runway into late 2027.

Kura Oncology announced robust second quarter 2026 financial results, highlighted by significant revenue growth for KOMZIFTI and promising clinical updates for its pipeline assets.

SKYX Platforms Corp. announced record second quarter 2026 revenues of $25.3 million, a 14% increase sequentially, and highlighted a 39% reduction in cash used in operating activities.

Coherent Corp. announced robust fourth quarter and full year fiscal 2026 financial results, showcasing significant year-over-year revenue growth, substantial margin expansion, and strong earnings per share.

ITG, Inc. announced robust second quarter 2026 financial results, showcasing 38% year-over-year revenue growth and a positive outlook for the full year, driven by strong demand in digital infrastructure services.

Comscore announced its second quarter 2026 financial results, reporting a decrease in revenue and an increase in net loss, alongside the completion of its Movies business sale and full debt repayment.

Omeros Corporation announced robust second quarter 2026 financial results, highlighted by a significant increase in YARTEMLEA revenue and improved operational cash flow.

Sky Harbour Group Corporation announced strong Q2 2026 financial results, including a 50% year-over-year revenue increase and the first-ever quarter of positive net cash from operations.

Red Robin Gourmet Burgers, Inc. announced its fiscal second quarter 2026 results, highlighting operational improvements and progress on its refranchising strategy.

U.S. Physical Therapy, Inc. provided an investor presentation on August 12, 2026, detailing its operational performance, strategic growth initiatives, and financial health.

Spero Therapeutics announced FDA approval for Utebzi, a $105 million financing deal, and a new licensing agreement for its SP001 program, extending cash runway into late 2029.